

David A Barrington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5247555/publications.pdf>

Version: 2024-02-01

12
papers

151
citations

1307594

7
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

184
citing authors

#	ARTICLE	IF	CITATIONS
1	More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 244.e1-244.e17.	1.3	8
2	Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2022, 165, 500-505.	1.4	6
3	Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases. <i>Gynecologic Oncology</i> , 2022, 165, 522-529.	1.4	5
4	Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy. <i>Gynecologic Oncology</i> , 2022, 166, 69-75.	1.4	1
5	Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2021, 162, 626-630.	1.4	11
6	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. <i>JCO Precision Oncology</i> , 2021, 5, 1588-1602.	3.0	15
7	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	2.5	10
8	Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes. <i>Gynecologic Oncology</i> , 2020, 158, 407-414.	1.4	16
9	Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. <i>Gynecologic Oncology</i> , 2019, 154, 379-382.	1.4	7
10	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2019, 153, 381-384.	1.4	28
11	Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. <i>Gynecologic Oncology</i> , 2018, 149, 337-340.	1.4	6
12	Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?. <i>Gynecologic Oncology</i> , 2016, 143, 617-621.	1.4	38